Clene Share Holder Equity 2018-2024 | CLNN

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Clene share holder equity from 2018 to 2024. Share holder equity can be defined as the sum of preferred and common equity items

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Clene share holder equity from 2018 to 2024. Share holder equity can be defined as the sum of preferred and common equity items

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$173B
Vertex Pharmaceuticals (VRTX)	$129.4B
Gilead Sciences (GILD)	$121.9B
Bristol Myers Squibb (BMY)	$111B
CSL (CSLLY)	$91.9B
Regeneron Pharmaceuticals (REGN)	$90.6B
GSK (GSK)	$76B
Argenex SE (ARGX)	$35.4B
Alnylam Pharmaceuticals (ALNY)	$35.1B
BioNTech SE (BNTX)	$25.7B
Biogen (BIIB)	$25.3B
Illumina (ILMN)	$24.6B
BeiGene (BGNE)	$20.1B
Moderna (MRNA)	$19.3B
Incyte (INCY)	$15.9B
Genmab (GMAB)	$15.3B
Insmed (INSM)	$12.8B
Vaxcyte (PCVX)	$12.8B
BioMarin Pharmaceutical (BMRN)	$12.8B
Bio-Techne Corp (TECH)	$12.1B
Sarepta Therapeutics (SRPT)	$11.5B
Exelixis (EXEL)	$10.2B
QIAGEN (QGEN)	$10.1B
Revolution Medicines (RVMD)	$9.9B
Exact Sciences (EXAS)	$9.9B
Intra-Cellular Therapies (ITCI)	$9.6B
Bio-Rad Laboratories (BIO.B)	$9.4B
Roivant Sciences (ROIV)	$8.7B
Repligen (RGEN)	$8.1B
Ascendis Pharma (ASND)	$7.7B